Early Discontinuation of Ethambutol in Pulmonary Tuberculosis Treatment Based on Results of the GenoType MTBDRplus Assay: a Prospective, Multicenter, Noninferiority Randomized Trial in South Korea | Zendy

KyungWook Jo | Zendy; Mi-Hye Kim | Zendy; YeJee Kim | Zendy; Hyun-Kyung Lee | Zendy; Hyun Kuk Kim | Zendy; Doosoo Jeon | Zendy; Jiwon Lyu | Zendy; Hye Kyeong Park | Zendy; Jeongha Mok | Zendy; Ju Sang Kim | Zendy; Eun Young Heo | Zendy; Sang Bong Choi | Zendy; JaeJoon Yim | Zendy; Tae Sun Shim | Zendy

Open Access

Early Discontinuation of Ethambutol in Pulmonary Tuberculosis Treatment Based on Results of the GenoType MTBDRplus Assay: a Prospective, Multicenter, Noninferiority Randomized Trial in South Korea

Author(s) -

KyungWook Jo,

Mi-Hye Kim,

YeJee Kim,

Hyun-Kyung Lee,

Hyun Kuk Kim,

Doosoo Jeon,

Jiwon Lyu,

Hye Kyeong Park,

Jeongha Mok,

Ju Sang Kim,

Eun Young Heo,

Sang Bong Choi,

JaeJoon Yim,

Tae Sun Shim

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00980-19

Subject(s) - medicine , discontinuation , ethambutol , regimen , tuberculosis , isoniazid , randomized controlled trial , rifampicin , guideline , adverse effect , multicenter trial , surgery , multicenter study , pathology

No studies have investigated whether the discontinuation of ethambutol (EMB) based on susceptibility to isoniazid and rifampin, as determined by the GenoType MTBDRplus assay, would be appropriate. We aimed to determine the feasibility of discontinuing EMB before the end of the intensive phase of treatment based on the results of the MTBDRplus assay in patients with pulmonary tuberculosis (PTB).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research